<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Envoy Medical Announces Pricing of Up to $78.0 Million Upsized Public Offering</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Envoy Medical Announces Pricing of Up to $78.0 Million Upsized Public Offering</h1>

    <table>
      <tr><th>Ticker</th><td>COCH</td></tr>
      <tr><th>Float</th><td>17.6 M</td></tr>
      <tr><th>IO</th><td>6.12%</td></tr>
      <tr><th>MC</th><td>10.2 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Envoy Medical (NASDAQ: COCH) priced an upsized public offering consisting of 75,000,000 shares of Class A common stock (or pre-funded warrants) together with Series A-1 warrants to purchase up to 45,000,000 shares and Series A-2 warrants to purchase up to 75,000,000 shares, at a combined public offering price of $0.40 per share (or pre-funded warrant) and accompanying warrants. The offering is expected to close on or about Feb. 12, 2026, with H.C. Wainwright & Co. as placement agent. Aggregate gross proceeds to the company at closing are expected to be approximately $30.0 million before fees, with potential additional gross proceeds of approximately $48.0 million if the warrants are fully exercised for cash following required stockholder approval and milestone events tied to FDA PMA submission and approval for the Acclaim cochlear implant. Envoy intends to use net proceeds for working capital and to fund operations during its FDA pivotal clinical study. The securities are offered under a registration statement on Form S-1 that was declared effective Feb. 11, 2026.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Provides approximately $30.0 million of immediate gross proceeds to fund operations and pivotal FDA study</li><li>Potential additional $48.0 million of cash proceeds if milestone-linked warrants are exercised</li><li>Registration statement (Form S-1) declared effective, enabling the offering to proceed</li><li>Placement agent (H.C. Wainwright) engaged to facilitate the offering</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Substantial dilution potential due to large number of shares and warrants being issued</li><li>Low offering price ($0.40) implies significant valuation pressure</li><li>Additional proceeds depend on warrant exercise and stockholder approval, which are uncertain</li><li>Material forward-looking milestone and timing risks tied to FDA PMA submission and approval</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/e254ec40-d58e-4bb4-b0a1-a5f2e70d7161" target="_blank">Original Article</a>
    </div>

    <div class="small">COCH â€¢ TradersLink AI News</div>
  </div>
</body>
</html>